Overview

Metastatic Solid Cancer Clinical Trial

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
Phase:
Phase 2
Details
Lead Sponsor:
ImmunSYS, LLC
Treatments:
Ipilimumab
Pembrolizumab
Sargramostim